Spexis AG in Liquidation
Company Overview
Previous Company Names
- Polyphor AG
- (PolyphorSA) (PolyphorLtd)
- Spexis AG
- (Spexis SA) (Spexis Ltd)
Management
Muriel Fleming
Unterägeri
Joint signing authority (any two to sign)
Bernard Bollag
London, GB
Member of the board
Joint signing authority (any two to sign)
Martin Jakobovic
Zürich
Joint signing authority (any two to sign)
Jeffrey Wager
Boston, US
Chairperson of the board
Joint signing authority (any two to sign)
Dennis Ausiello
Wellesley Hills, US
Vice-chairperson of the board
Joint signing authority (any two to sign)
Robert Clarke
Medfield, US
Member of the board
Joint signing authority (any two to sign)
Daniel Hartmann
Kirkland, US
Member of the board
Joint signing authority (any two to sign)
Kuno Sommer
Basel
Member of the board
Joint signing authority (any two to sign)
Peter Zbinden
Magden
Joint signing authority (any two to sign)
Johann Zimmermann
Auggen (DE)
Joint signing authority (any two to sign)
Jean-Pierre Obrecht
Riehen
Chairperson of the board
Joint signing authority (any two to sign)
Jack Baldwin
Oxford(UK)
Member of the board
Joint signing authority (any two to sign)
Daniel Obrecht
Basel
Member of the board
Joint signing authority (any two to sign)
Peter Grogg
Bubendorf
Member of the board
Joint signing authority (any two to sign)
Thomas Früh
Magden
Member of the board
Joint signing authority (any two to sign)
Dr. Meier
Allschwil
Member of the board
Joint signing authority (any two to sign)
Michael Altorfer
Zürich
Member of the management board
Joint signing authority (any two to sign)
Philipp Ermert
Allschwil
Joint signing authority (any two to sign)
Dr. Thomas Maetzke
Münchenstein
Joint signing authority (any two to sign)
Jean-Pierre Obrecht
Basel
Managing member of the board
Joint signing authority (any two to sign)
Building smart people network graph...
Fetching people and their companies
Address & Locations
Primary Address
Loading map...
| No. | Journal No. | Journal date | SOGC | SOGC date | Page / ID |
|---|---|---|---|---|---|
| 1 | B4182 | 28.07.2025 | B146 | 31.07.2025 | 1006398903 |
| 2 | 7228 | 19.12.2024 | 250 | 24.12.2024 | 1006215210 |
| 3 | 4807 | 27.08.2024 | 168 | 30.08.2024 | 1006118366 |
| 4 | 4327 | 26.07.2024 | 147 | 31.07.2024 | 1006097966 |
| 5 | 4277 | 23.07.2024 | 144 | 26.07.2024 | 1006094889 |
| 6 | 2124 | 11.04.2024 | 73 | 16.04.2024 | 1006010100 |
| 7 | 1151 | 20.02.2024 | 38 | 23.02.2024 | 1005969304 |
| 8 | 6616 | 05.12.2023 | 239 | 08.12.2023 | 1005905171 |
| 9 | 5420 | 06.10.2023 | 197 | 11.10.2023 | 1005858066 |
| 10 | 4038 | 18.07.2023 | 140 | 21.07.2023 | 1005801338 |
Company Purpose
Der Zweck der Gesellschaft besteht in der Forschung, Entwicklung und Herstellung von Medikamenten, deren Inhaltsstoffen und deren Vermarktung sowie in allen damit verbundenen Tätigkeiten. Die Gesellschaft kann sich anderen Gesellschaften beteiligen. Die Gesellschaft kann alle kommerziellen, vertraglichen, finanziellen sowie alle anderen Geschäfte eingehen, welche geeignet sind, den Zweck der Gesellschaft zu fördern oder damit direkt oder indirekt im Zusammenhang stehen. Die Gesellschaft kann Zweigniederlassungen im In- und Ausland errichten, sich ananderen Gesellschaften beteiligen oder sich mit solchen zusammenschliessen. Die Gesellschaft kann Garantien oder andere Sicherheiten bezüglich Verbindlichkeiten oder Tochtergesellschaften abgeben. Ferner kann die Gesellschaft Grundeigentum erwerben, halten und veräussern.